Device therapies: new indications and future directions

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT), and combination (CRT-D) devices are crucial for managing heart failure with reduced ejection fraction (HFrEF).
• ICDs prevent sudden cardiac death from ventricular arrhythmias, while CRT enhances left ventricular systolic function through ventricular resynchronization.

Purpose of the Study:

• To review the role and advancements of device therapies (ICD, CRT-D) in HFrEF management.
• To highlight the benefits, complications, and future research directions for these cardiac devices.

Main Methods:

• Literature review of current device therapies for HFrEF.
• Analysis of clinical outcomes, including mortality and hospitalization rates.
• Discussion of device-related complications and technological advancements.

Main Results:

• Device therapies (ICD, CRT-D) significantly reduce all-cause mortality and sudden cardiac death in HFrEF patients.
• CRT and CRT-D therapies are associated with reduced hospitalization rates.
• Major complications include device infection, inappropriate shocks, and lead issues.

Conclusions:

• ICD, CRT, and CRT-D therapies are established treatments for HFrEF, improving survival and reducing hospitalizations.
• Continuous improvements in device technology and implantation techniques aim to enhance efficacy and minimize complications.
• Further research is needed to refine patient selection for optimal benefit from these device therapies.